Polish regulators report surge in counterfeit Ozempic sales via online channels

The Polish Office for Registration of Medicinal Products has identified a growing illicit market for counterfeit Ozempic, citing systemic loopholes exploited by online vendors. While the exact scale of the distribution remains unquantified, the admission signals a widening regulatory challenge in monitoring pharmaceutical supply chains.